Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

Published 2019-07-09, 07:45 a/m
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
NOVN
-
VTRS
-
DMKPQ
-

July 9 (Reuters) - A unit of Novartis AG NOVN.S said on Tuesday it would make partner Adamis Pharmaceuticals Corp's ADMP.O emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's MYL.O rival product, EpiPen.

The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner. dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.

However, there has been a shortage of EpiPens in North America, Europe and Canada due to manufacturing delays. The U.S. Food and Drug Administration in May last year added the treatment to its list of drugs in shortage.

Adamis, which received U.S. approval for its emergency epinephrine syringes in 2017, distributes Symjepi in the United States exclusively through Sandoz.

In a statement, Sandoz said it was making both the adult and pediatric doses of Symjepi immediately available in local pharmacies across the nation.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.